MAWAG
EDIT icon

Mid-American Wealth Advisory Group’s Editas Medicine EDIT Stock Holding History

Mid-American Wealth Advisory Group’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-40
Closed -$88 – 121
2025
Q2 		$88 Buy
+40
New +$65 ﹤0.01% 334

Other funds holding EDIT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Mid-American Wealth Advisory Group's EDIT Position: Q3 2025 in Review

Mid-American Wealth Advisory Group sold out of Editas Medicine (EDIT) in Q3 2025, closing a stake of 40 shares — an estimated $88 sold.

Mid-American Wealth Advisory Group first reported a position in EDIT in Q2 2025 and held it in 1 quarter. The position peaked at $88 in Q2 2025. 193 funds tracked by Wall St. Rank hold EDIT as of Q3 2025.

  • Mid-American Wealth Advisory Group reported no remaining Editas Medicine position as of Q3 2025 after selling out during the quarter.
  • Mid-American Wealth Advisory Group sold 40 Editas Medicine shares in Q3 2025, an estimated $88.
  • Mid-American Wealth Advisory Group first reported a position in Editas Medicine in Q2 2025 and held it in 1 quarter.
  • Mid-American Wealth Advisory Group's Editas Medicine position peaked at $88 in Q2 2025.
  • 193 funds tracked by Wall St. Rank held Editas Medicine as of Q3 2025.

Based on Mid-American Wealth Advisory Group's 13F filing for Q3 2025, filed 20 Oct 2025.